Inside a partnership showing how open-source platforms and startups are scaling autonomous driving beyond the lab.
Updated
January 8, 2026 6:30 PM
.jpg)
A Robotaxi prototype developed by TIER IV. PHOTO: TIER IV
Autonomous driving is often discussed in terms of futuristic cars and distant timelines. This investment is about something more immediate. Japan-based TIER IV has invested in Turing Drive, a Taiwan startup that builds autonomous driving systems designed for controlled, everyday environments such as factories, ports, airports and industrial campuses. The investment establishes a capital and business alliance between the two companies, with a shared focus on developing autonomous driving technology and expanding operations across Asia.
Rather than targeting open roads and city traffic, Turing Drive’s work centres on places where vehicles follow fixed routes and move at low speeds. These include logistics hubs, manufacturing facilities and commercial sites where automation is already part of daily operations. According to the release, Turing Drive has deployments across Taiwan, Japan and other regions and works closely with vehicle manufacturers to integrate autonomous systems into special-purpose vehicles.
The investment also connects Turing Drive more closely with Autoware, an open-source autonomous driving software ecosystem supported by TIER IV. Turing Drive joined the Autoware Foundation in September 2024 and develops its systems using this shared software framework. TIER IV’s own Pilot.Auto platform, which is built around Autoware, is used across applications such as factory transport, public transit, freight movement and autonomous mobility services.
Through the alliance, TIER IV plans to work with Turing Drive to further develop autonomous driving systems for these controlled environments, while strengthening its presence in Taiwan and the broader Asia-Pacific region. The collaboration brings together software development and on-the-ground deployment experience within markets where autonomous driving is already being tested in real operational settings.
“This partnership with Turing Drive represents a significant step forward in accelerating the deployment of autonomous driving across Asia”, said TIER IV CEO Shinpei Kato. “At TIER IV, our mission has always been to make autonomous driving accessible to all. By collaborating with Turing Drive, which has demonstrated remarkable achievements in real-world deployments in Taiwan, we aim to deliver autonomous driving that enables a safer, more sustainable and more inclusive society”.
“We are thrilled to establish this strategic alliance with TIER IV, a global leader in open-source autonomous driving”, said Weilung Chen, chairman of Turing Drive. “In Taiwan, autonomous driving deployment is gaining significant momentum, particularly across logistics hubs, ports, airports and industrial campuses. By combining our field expertise with TIER IV's world-class Pilot.Auto platform, we aim to accelerate the development of practical, commercially viable mobility services powered by autonomous driving”. Overall, the investment highlights how autonomous driving in Asia is being shaped by operational needs and gradual integration, rather than headline-grabbing demonstrations.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.